Elena Seminari

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. ncbi Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients
    Elena Seminari
    Infectious Disease Department, San Raffaele Scientific Institute, Via Stamira d Ancona 20, 20122 Milan, Italy
    J Antimicrob Chemother 56:790-2. 2005
  2. ncbi Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients
    E Seminari
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    HIV Med 6:145-50. 2005
  3. ncbi Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment
    Elena Seminari
    Infectious Disease Department, San Raffaele Scientific Institute and Universita Vita Salute San Raffaele, Via Stamina d Ancona 20, 20122 Milan, Italy
    J Antimicrob Chemother 60:831-6. 2007
  4. ncbi Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients
    Elena Seminari
    Infectious Disease Department, San Raffaele Scientific Institute, Vita Salute University, Via Stamira d Ancona 20, 20122 Milan, Italy
    Eur J Clin Pharmacol 61:545-9. 2005
  5. ncbi Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS Res Hum Retroviruses 21:545-54. 2005
  6. doi Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients
    Vincenzo Spagnuolo
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Acquir Immune Defic Syndr 50:192-5. 2009
  7. ncbi Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels
    Vincenzo Spagnuolo
    Infectious Disease Department, San Raffaele Scientific Institute and Università Vita Salute San Raffaele Milan, Italy
    New Microbiol 30:279-82. 2007
  8. ncbi Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
    Hamid Hasson
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 18:123-7. 2004
  9. doi Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial
    Alessandro Soria
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Clin Virol 47:253-7. 2010
  10. ncbi Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:119-25. 2005

Detail Information

Publications19

  1. ncbi Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients
    Elena Seminari
    Infectious Disease Department, San Raffaele Scientific Institute, Via Stamira d Ancona 20, 20122 Milan, Italy
    J Antimicrob Chemother 56:790-2. 2005
    ..The aim of this study was to evaluate the correlation between liver function markers (necrosis and cholestasis) and plasma lopinavir levels in a cohort of HIV-infected patients treated with lopinavir and ritonavir...
  2. ncbi Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients
    E Seminari
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    HIV Med 6:145-50. 2005
    ..To characterize osteoprotegerin (OPG) levels, bone remodelling and bone mineral density (BMD) in heavily pretreated HIV-infected patients on antiretroviral therapy, and to evaluate the clinical factors associated with bone density decline...
  3. ncbi Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment
    Elena Seminari
    Infectious Disease Department, San Raffaele Scientific Institute and Universita Vita Salute San Raffaele, Via Stamina d Ancona 20, 20122 Milan, Italy
    J Antimicrob Chemother 60:831-6. 2007
    ..The purpose of this study was to evaluate the steady-state pharmacokinetics of amprenavir and ritonavir in HIV-infected patients with different degrees of hepatic impairment...
  4. ncbi Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients
    Elena Seminari
    Infectious Disease Department, San Raffaele Scientific Institute, Vita Salute University, Via Stamira d Ancona 20, 20122 Milan, Italy
    Eur J Clin Pharmacol 61:545-9. 2005
    ..The aim of this pilot study was to examine the pharmacokinetics of atazanavir (ATV) when given in combination with amprenavir (APV) or saquinavir hard-gel capsules (SQV) to human immunodeficiency virus (HIV)-positive patients...
  5. ncbi Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS Res Hum Retroviruses 21:545-54. 2005
    ..In highly PI-experienced patients, a PI-sparing regimen may lead to a reduction, no change, or increase in the number of PI mutations. The reduction is negligible in most cases...
  6. doi Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients
    Vincenzo Spagnuolo
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Acquir Immune Defic Syndr 50:192-5. 2009
    ..To evaluate changes in resistance to tipranavir/r (TPV/r) and darunavir/r (DRV/r) in patients who had failed a TPV/r-including regimen...
  7. ncbi Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels
    Vincenzo Spagnuolo
    Infectious Disease Department, San Raffaele Scientific Institute and Università Vita Salute San Raffaele Milan, Italy
    New Microbiol 30:279-82. 2007
    ..2002). The aim of this study was to evaluate the liver function tests in HCV-co-infected patients treated with fos-amprenavir and ritonavir...
  8. ncbi Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
    Hamid Hasson
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 18:123-7. 2004
    ..Treatment with LPV/r can select for the 50 V mutation. In this setting, significant differences in the inference of the amprenavir phenotype from genotype were observed when using different algorithms...
  9. doi Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial
    Alessandro Soria
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Clin Virol 47:253-7. 2010
    ..In HIV-1-infected patients harbouring the M184V mutation (M184V), lamivudine monotherapy leads to a smaller decrease in CD4 percentages (CD4%) than treatment interruption, possibly due to the reduced fitness of the mutated virus...
  10. ncbi Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:119-25. 2005
    ..In conclusion, the number of ATV resistance mutations is the only correlate to virological response through 24 weeks of treatment with unboosted atazanavir 400 mg once daily...
  11. doi Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy
    Antonella Castagna
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 15:165-75. 2010
    ..The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined...
  12. ncbi Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 18:2205-8. 2004
    ..After a median of 26 weeks of treatment, two patients (10%) selected the 65R mutation. These results support the hypothesis that NEM hinder the selection of this mutation...
  13. pmc Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients
    Daria Trabattoni
    Cattedra di Immunologia, Universita di Milano, DISP, LITA Vialba, Milan, Italy
    Clin Diagn Lab Immunol 9:1114-8. 2002
    ..Therapy with EFV, NFV, and d4T increases HIV-specific type 1 cytokine production as well as CD4 counts and reduces plasma viremia. This therapeutic regimen may be considered for use in cases of advanced HIV infection...
  14. ncbi Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals
    Daria Trabattoni
    Department of Immunology, University of Milan, Via GB Grassi 74, 20157 Milan, Italy
    AIDS 18:859-69. 2004
    ..CTL are stimulated by type 1 cytokines and can kill targets via granule-dependent (perforin and granzymes) and -independent (tumour necrosis factor-alpha, CD95) mechanisms...
  15. ncbi Sex differences in nevirapine disposition in HIV-infected patients
    Mario Regazzi
    Departments of Pharmacology and Infectious Diseases, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    AIDS 17:2399-400. 2003
  16. ncbi Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response
    Daniele Lilleri
    Servizio di Virologia, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    J Clin Virol 26:95-100. 2003
    ..However, cases of HCMV disease in HIV-infected patients treated with HAART have been reported...
  17. ncbi Haemostatic activation in HIV infected patients treated with different antiretroviral regimens
    Angelo Pan
    Istituto di Malattie Infettive e Tropicali, Spedali Civili, Universita di Brescia, Brescia, Italy
    Curr HIV Res 6:70-6. 2008
    ..In conclusion, a) HIV infection per se may alter the haemostatic markers of cardiovascular risk, b) minor differences were observed among the different classes of HIV infected patients, namely between NNRTI and PI treated patients...
  18. ncbi Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients
    Mario Clerici
    Cattedra di Immunologia, Universita degli Studi di Milano, DISP LITA Vialba, Milano, Italy
    AIDS 16:1767-73. 2002
    ..Control of HIV replication can be observed in highly active antiretroviral therapy (HAART)-treated and, occasionally, in HAART-naive patients. The immunological correlates of these situations were examined in a longitudinal study...
  19. ncbi Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses
    Franco Lori
    Research Institute for Genetic and Human Therapy RIGHT at IRCCS Policlinico S Matteo, Pavia, Italy
    HIV Clin Trials 3:115-24. 2002
    ..To study whether and under what circumstances HIV can be controlled in chronically infected patients...